205055-10-3

Basic information

• Product Name: Benzo[b]thiophene, 6-fluoro- (9CI)
• Synonyms: Benzo[b]thiophene, 6-fluoro- (9CI);6-fluorobenzo[b]thiophene;6-fluoro-1-benzothiophene
• CAS NO: 205055-10-3
• Molecular Formula: C8H5FS
• Molecular Weight: 152.1887032
• Product Categories: HALIDE
• Mol File: 205055-10-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 226.2±13.0 °C(Predicted)
• Appearance: /
• Density: 1.298±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzo[b]thiophene, 6-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzo[b]thiophene, 6-fluoro- (9CI)(205055-10-3)
• EPA Substance Registry System: Benzo[b]thiophene, 6-fluoro- (9CI)(205055-10-3)

Safety Data

• Hazardous Substances Data: 205055-10-3(Hazardous Substances Data)

Usage

General Description

Benzo[b]thiophene, 6-fluoro- (9CI) is a chemical compound with the molecular formula C8H5FS. It is a heterocyclic aromatic compound that contains a fluorine atom attached to the sixth position of the benzo[b]thiophene ring. This chemical is commonly used in research and development as a building block for the synthesis of various organic compounds. It is also used as a precursor in the production of pharmaceuticals and agrochemicals. Benzo[b]thiophene, 6-fluoro- (9CI) is known for its potential biological and pharmacological activities, and it is being studied for its potential applications in the field of medicine and drug discovery. However, it is important to handle this chemical with caution and follow safety protocols due to its potential hazards and risks.

Upstream product

• 550998-52-2 6-fluorobenzo[b]thiophene-2-carboxylic acid methyl ester 
• 501944-64-5 3-fluorobenzenethioacetaldehyde diethyl acetal 
• 1550-35-2 2,4-difluorobenzaldehyde 
• 142329-23-5 6-fluorobenzo[b]thiophene-2-carboxylic acid 
• 1098607-88-5 6-fluoro-1-benzothiophen-3(2H)-one 
• 212078-68-7 6-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester 

Downstream Products

• 324769-21-3 C₂₇H₃₂FNO₄SSi 
• 324769-20-2 1-benzyl-3-methyl-4-hydroxy-4-(2-trimethylsilyl-6-fluorobenzothien-7-yl)piperidine 
• 212078-69-8 1-(6-fluorobenzo[b]thiophen-2-yl)-3-(1-triphenylmethyl-1H-imidazol-4-yl)-propan-1-ol 

Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

Indole derivatives for the treatment of depression and anxiety

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors.

Novel nonsteroidal C(17,20)-lyase inhibitors were synthesized using de novo design based on its substrate, 17 alpha-hydroxypregnenolone, and several compounds exhibited potent C(17,20)-lyase inhibition. However, in vivo activities were found to be short-lasting, and in order to improve the duration of action, a series of benzothiophene derivatives were evaluated. As a result, compounds 9h, (S)-9i, and 9k with nanomolar enzyme inhibition (IC(50)=4-9 nM) and 9e (IC(50)=27 nM) were identified to have powerful in vivo efficacy with extended duration of action. The key structural determinants for the in vivo efficacy were demonstrated to be the 5-fluoro group on the benzothiophene ring and the 4-imidazolyl moiety. Superimposition of 9k and 17 alpha-hydroxypregnenolone demonstrated their structural similarity and enabled rationalization of the pharmacological results. In addition, selected compounds were also identified to be potent inhibitors of human enzyme with IC(50) values of 20-30 nM.